Does TMB Impact the Effectiveness of TKIs in <i>EGFR</i>-Mutant NSCLC?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 30190372.
- Also identified by DOI 10.1158/1078-0432.CCR-18-2368 and PMC identifier 6359945.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Patients with <i>EGFR</i>-mutant non-small cell lung cancer achieve variable benefit from targeted therapy, and biomarkers to predict degree of benefit are not in clinical use. <i>EGFR</i>-mutant cancers with high tumor mutational burden demonstrate poorer outcomes on EGFR-targeted therapy. Investigation into the mechanisms underlying this intriguing association is needed.<i>See related article by Offin et al., p. 1063</i>.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms